Nordic Capital, Wendel in two-way race for $1.6B LTS Lohmann deal

Two buyout firms are duking it out for LTS Lohmann, a drug-patch maker partly owned by Novartis ($NVS), Reuters reports. Now that the dust has settled on first-round bids, which were due last month, Wendel and Nordic Capital are still in the running for a deal worth about $1.6 billion.

LTS Lohmann makes nicotine patches and other transdermal drugs, including treatments for Parkinson's disease and restless-legs syndrome. According to Reuters, the company brings in about €286 million ($386.7 million) in annual sales.

For Nordic Capital, buying LTS Lohmann would offer the opportunity to merge its operations with a skin-patch maker it bought last month. Nordic and private equity partner Avista Capital Partners together bought Switzerland-based Acino, which turns out a birth-control patch for Bayer, among other products.

Blackstone had similar ideas; the firm had been chasing after LTS Lohmann with an eye to combining it with Catalent, which also does contract manufacturing. Both Blackstone and KKR--which owns Capsugel, a capsule-making business once owned by Pfizer ($PFE)--have lost interest, however, Reuters' sources say.

Drugs delivered via skin patch are increasingly common as drugmakers look for new ways to sell old products. Beyond the usual skin-patch categories--such as painkillers, nicotine and hormonal birth control--drugmakers are selling a migraine treatment patch (Nupathe's Zecuity) and an Alzheimer's drug patch (Exelon, Novartis), among many others.

In fact, Novartis is LTS Lohmann's biggest customer. The Swiss drugmaker owns 43% of the company and relies on it for patch manufacturing. Another 30% is in the hands of German billionaire Dietmar Hopp, and Germany's BWK controls the rest.

- get the story from Reuters

Special Report: Top Biopharma M&A Deals 2012

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.